Next Article in Journal
Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond
Previous Article in Journal
Can Less Be More? Organ Preservation Strategies in the Management of Rectal Cancer
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease

by 1, 1,2 and 1,*
1
Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room T2-044, Toronto, ON M4N 3M5, Canada
2
Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(s1), 24-32; https://0-doi-org.brum.beds.ac.uk/10.3747/co.26.5575
Received: 7 August 2019 / Revised: 9 September 2019 / Accepted: 13 October 2019 / Published: 1 November 2019
Therapeutic options for chemorefractory metastatic colorectal cancer (mcrc) have significantly expanded since 2009. The oral targeted therapies regorafenib and trifluridine/tipiracil have been established to be efficacious and safe in patients with mcrc who have progressed beyond 2 or more lines of chemotherapy. Evidence for the use of immunotherapy in a subgroup of this patient population is also encouraging, particularly in patients with mcrc that exhibits high microsatellite instability or deficient mismatch repair. Those significant advances have led to Health Canada approval of 3 novel therapeutic options for the treatment of patients with chemorefractory mcrc. However, the limited clinical efficacy of those treatments underscores the need for ongoing development of systemic therapy options for this unique cohort of patients. Here, we review the current and emerging treatment landscape for chemorefractory mcrc.
Keywords: colorectal cancer; metastatic; targeted therapy; immunotherapy; treatment-refractory disease colorectal cancer; metastatic; targeted therapy; immunotherapy; treatment-refractory disease
MDPI and ACS Style

Parmar, A.; Chan, K.K.W.; Ko, Y.J. Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. Curr. Oncol. 2019, 26, 24-32. https://0-doi-org.brum.beds.ac.uk/10.3747/co.26.5575

AMA Style

Parmar A, Chan KKW, Ko YJ. Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. Current Oncology. 2019; 26(s1):24-32. https://0-doi-org.brum.beds.ac.uk/10.3747/co.26.5575

Chicago/Turabian Style

Parmar, A., K.K.W. Chan, and Y.J. Ko 2019. "Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease" Current Oncology 26, no. s1: 24-32. https://0-doi-org.brum.beds.ac.uk/10.3747/co.26.5575

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop